Blitzima A Boost For Adcock As It Scoops Up New Rituximab Patients
South African Firm In-Licenses Biosimilar Cancer Drug From Celltrion
Executive Summary
South Africa’s Adcock Ingram gave a sprawling update of its operations for the first half of its financial year ending in June 2022, which saw a rise in sales but a decline in profit for its Prescription business.